Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
The results of our study show that pathological assessment following NAC offers valuable insights into the survival outcome of HER2-low breast cancer. According to these findings, responses to NAC should be considered when choosing systemic treatment for patients with HER2-low breast cancer.
Authors
- Chaojun Liu (ORCID: https://orcid.org/0000-0002-4676-3981)
- Zhifen Luo
- Qi Chen (ORCID: https://orcid.org/0000-0002-0640-6859)
- Huijuan Guan (ORCID: https://orcid.org/0000-0001-7595-3082)
- Hui Liu (ORCID: https://orcid.org/0000-0003-2231-0870)
- Yang Yu (ORCID: https://orcid.org/0000-0002-8482-4626)
- Fangyuan Zhu
- Yaning He
- Yingbo Shao
Institutions
- Henan University (CN)
- Zhengzhou University (CN)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3389/fonc.2025.1459444
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00